Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stavzor valproic acid regulatory update

NOVN said FDA issued an approvable letter for an NDA for Stavzor valproic acid to treat seizures,

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE